Trial · NCT02453282
Results by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 126
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy | Durvalumab Monotherapy | 16.3 | 95% Confidence Interval 12.2 to 20.8 | months | |
| Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy | Durvalumab + Tremelimumab | 11.9 | 95% Confidence Interval 9.0 to 17.7 | months | |
| Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy | SoC Chemotherapy | 12.9 | 95% Confidence Interval 10.5 to 15.0 | months | |
| Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy | Durvalumab + Tremelimumab | 3.9 | 95% Confidence Interval 2.8 to 5.0 | months | |
| Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy | SoC Chemotherapy | 5.4 | 95% Confidence Interval 4.6 to 5.8 | months | |
| OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy | Durvalumab Monotherapy | 16.3 | 95% Confidence Interval 12.2 to 20.8 | months | |
| OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy | Durvalumab + Tremelimumab | 11.9 | 95% Confidence Interval 9.0 to 17.7 | months | |
| OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy | SoC Chemotherapy | 12.9 | 95% Confidence Interval 10.5 to 15.0 | months | |
| OS; PD-L1 (TC >=1%) Analysis Set Population | Durvalumab Monotherapy | 14.6 | 95% Confidence Interval 10.5 to 17.7 | months | |
| OS; PD-L1 (TC >=1%) Analysis Set Population | Durvalumab + Tremelimumab | 10.9 | 95% Confidence Interval 9.1 to 13.5 | months | |
| OS; PD-L1 (TC >=1%) Analysis Set Population | SoC Chemotherapy | 12.3 | 95% Confidence Interval 10.6 to 14.6 | months | |
| OS; FAS Population | Durvalumab Monotherapy | 12.3 | 95% Confidence Interval 10.1 to 14.9 | months | |
| OS; FAS Population | Durvalumab + Tremelimumab | 11.2 | 95% Confidence Interval 9.5 to 12.9 | months | |
| OS; FAS Population | SoC Chemotherapy | 11.8 | 95% Confidence Interval 10.5 to 13.3 | months | |
| PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy | Durvalumab Monotherapy | 4.7 | 95% Confidence Interval 3.1 to 6.3 | months | |
| PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy | Durvalumab + Tremelimumab | 3.9 | 95% Confidence Interval 2.8 to 5.0 | months | |
| PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy | SoC Chemotherapy | 5.4 | 95% Confidence Interval 4.6 to 5.8 | months | |
| PFS; PD-L1 (TC >=1%) Analysis Set Population | Durvalumab Monotherapy | 3.6 | 95% Confidence Interval 2.8 to 4.2 | months | |
| PFS; PD-L1 (TC >=1%) Analysis Set Population | Durvalumab + Tremelimumab | 2.8 | 95% Confidence Interval 2.5 to 3.4 | months | |
| PFS; PD-L1 (TC >=1%) Analysis Set Population | SoC Chemotherapy | 5.5 | 95% Confidence Interval 4.9 to 5.7 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02453282/results